What is NNNN's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.47B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for NNNN?

P/E (TTM) is 46.12 and 52-week range is $3.09 to $44.73 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s NNNN figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for NNNN?

The company profile lists revenue (TTM) near $13M, net income (TTM) near $10M, EPS (TTM) near $0.23 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Anbio Biotechnology based, and what identifiers does Chartloom list?

The company context section lists headquarters in Frankfurt, Hessen, DE, 43.9M shares outstanding, ISIN KYG0367B1059 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Anbio Biotechnology

$NNNN

Health Care · Biotechnology

Run Scenarios

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Anbio Biotechnology is a medical device company. The company is headquartered in Frankfurt, Hessen and currently employs 27 full-time employees. The company went IPO on 2025-02-19. The firm is engaged in the development of medical technology and the provision of in vitro diagnostics (IVD) products. Its products offer solutions for over the counter (OTC) use, point-of-care (POCT) settings, and laboratory applications, ensuring that both healthcare providers and patients have access to reliable and efficient diagnostic tools in any setting. Its IVD products detect a wide range of biomarkers across critical medical fields, including infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Some of its IVD platforms: Chemiluminescence Immunoassay (ChLIA), Lateral Flow Immunoassay (LFIA), Fluorescent Immunoassay (FIA), Polymerase Chain Reaction (PCR) and Loop-mediated Isothermal Amplification (LAMP).

Employees

Website

anbiobiotechnology.com/

IPO

2025-02-19

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)